- Home
- RNAC
as 11-15-2024 4:00pm EST
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREDERICK |
| Market Cap: | 472.7M | IPO Year: | 2016 |
| Target Price: | $40.80 | AVG Volume (30 days): | 107.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.67 - $42.60 | Next Earning Date: | 11-07-2024 |
| Revenue: | $47,938,000 | Revenue Growth: | -62.40% |
| Revenue Growth (this year): | 69.22% | Revenue Growth (next year): | -83.00% |
Stock Insider Trading Activity of Cartesian Therapeutics Inc. (RNAC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Oct 2 '24 | Buy | $20.91 | 205,721 | $4,293,544.83 | 7,823,559 |
Latest Cartesian Therapeutics Inc. News
RNAC Breaking Stock News: Dive into RNAC Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 days ago
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024
GlobeNewswire
9 days ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
10 days ago
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
12 days ago
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
Simply Wall St.
a month ago
Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock
GlobeNewswire
a month ago
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 10/07/2024
GlobeNewswire
a month ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Compare RNAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAC Cartesian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.